Delving into the Latest Updates on ZHB-206 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

+ [4]

Target-

Mechanism-

Therapeutic Areas

Nervous System DiseasesCardiovascular Diseases

Active Indication

Acute Ischemic Stroke

Inactive Indication-

Originator Organization

Changzhou Qianhong Biopharma Co., Ltd.

Active Organization

Changzhou Qianhong Biopharma Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

The primary objective is to evaluate the tolerability and safety of single and multiple doses of QHRD106 injection in healthy Chinese subjects, and provide a basis for subsequent clinical trials. The secondary objective is to evaluate the pharmacokinetic characteristics of QHRD106 injection in healthy Chinese subjects.

Start Date10 Mar 2023

Sponsor / Collaborator

Zonhon Biopharma Institute, Inc.

[+1]

NCT06388772

/ CompletedPhase 1

Phase I Clinical Study of Tolerability, Safety and Pharmacokinetics of QHRD106 Injection in Chinese Healthy Subjects With Single Doses

The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of QHRD106 early in Chinese healthy subjects with single doses.

Start Date05 Jul 2021

Sponsor / Collaborator

Changzhou Qianhong Biopharma Co., Ltd.

100 Clinical Results associated with ZHB-206

Login to view more data

100 Translational Medicine associated with ZHB-206

Login to view more data

100 Patents (Medical) associated with ZHB-206

Login to view more data

2

Literatures (Medical) associated with ZHB-206

01 Dec 2024·Expert Opinion on Investigational Drugs

The first-in-human study of QHRD106 functioning as a safe and effective long-acting kallikrein drug potentially aiding ischemic stroke

Article

Author: Huang, Lei ; Zhang, Yuwen ; Song, Hengwen ; Chen, Zhiyou ; Sun, Runbin ; Fei, Fei ; Yang, Haoyi ; Wei, Lijun ; Hong, Yuxin ; Li, Juan

BACKGROUNDThis study assessed the pharmacokinetics (PK), pharmacodynamics (PD) and safety of QHRD106, and made a comparison with urinary kallindinogenase (UKN) in healthy volunteers.METHODSThis study comprised a randomized, double-blind, placebo-controlled, single-dose escalation phase and an open-label, multiple-dose escalation phase. Ninety-four subjects received intramuscular injections of QHRD106/placebo only once and 30 subjects received QHRD106 four times. Six subjects received 0.15 PNA units UKN intravenously for 7 d. PK and PD analysis were conducted by using a electrochemiluminescent assay and a liquid chromatography/mass spectrometry methodology, respectively. Cerebral circulation was assessed by the magnetic resonance imaging system.RESULTSQHRD106 exhibited a slow absorption profile in the human body. Compared to UKN, QHRD106-induced changes in bradykinin concentration later, but with a noticeably prolonged duration. Compared to baseline, cerebral blood flow exhibited a significant improvement on d 7 after a single dose of 18,900 IU and an improvement from d 2 to d 14 after multiple doses of 8400 IU of QHRD106. QHRD106 appeared generally good safety and no severe adverse events occurred in all the groups.CONCLUSIONSThis study provided initial evidence of potential treatment for ischemic strokes that the QHRD106 injection functioned as a safe and effective long-acting kallikrein drug.REGISTRATIONThis study was registered on ClinicalTrials.gov with the identifier NCT06380699 and NCT06388772.

01 Jul 2023·iScience

QHRD106 ameliorates ischemic stroke injury as a long-acting tissue kallikrein preparation

Article

Author: Cao, Xiang ; Bao, Xin-Yu ; Sun, Min ; Xu, Yun ; Liu, Pin-Yi ; Jia, Jun-Qiu ; Xia, Sheng-Nan ; Ji, Sen-Lin ; Shu, Shu ; Ye, Lei ; Xu, Si-Yi

Ischemic stroke is the second leading cause of death worldwide, and there are limited effective treatment strategies. QHRD106, a polyethyleneglycol (PEG)-modified long-acting tissue kallikrein preparation, has not been reported previously. In this study, we aimed to investigate the therapeutic effect of QHRD106 in ischemic stroke and its possible mechanism. We found that QHRD106 treatment alleviated brain injury after stroke via bradykinin (BK) receptor B2 (B2R) instead of BK receptor B1 (B1R). Mechanistically, QHRD106 reduced high-mobility group box 1 (HMGB1)-induced apoptosis and inflammation after ischemic stroke in vivo and in vitro. Moreover, we confirmed that QHRD106 reduced the level of acetylated HMGB1 and reduced the binding between heat shock protein 90 alpha family class A member 1 (HSP90AA1) and HMGB1, thus inhibiting the translocation and release of HMGB1. In summary, these findings indicate that QHRD106 treatment has therapeutic potential for cerebral ischemic stroke.

100 Deals associated with ZHB-206

Login to view more data